# First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

> **NCT07505043** · PHASE1 · NOT_YET_RECRUITING · sponsor: **SUNHO（China）BioPharmaceutical CO., Ltd.** · enrollment: 104 (estimated)

## Conditions studied

- Healthy Subjects
- Hyperlipidemia, Hypertriglyceridemia

## Interventions

- **DRUG:** ISH0688 for injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07505043
- **Lead sponsor:** SUNHO（China）BioPharmaceutical CO., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-01
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07505043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07505043, "First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07505043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*